Vericel (NASDAQ:VCEL) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Vericel (NASDAQ:VCEL) released its quarterly earnings results on Thursday. The biotechnology company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.31 by $0.07, Zacks reports. Vericel had a net margin of 1.56% and a return on equity of 1.48%.

Vericel Stock Down 6.1 %

NASDAQ VCEL traded down $3.23 on Thursday, reaching $49.62. The company had a trading volume of 669,939 shares, compared to its average volume of 401,498. The stock has a market capitalization of $2.45 billion, a PE ratio of 827.14 and a beta of 1.72. The firm’s 50 day moving average price is $57.41 and its 200 day moving average price is $51.76. Vericel has a 12 month low of $39.12 and a 12 month high of $63.00.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Stephens reaffirmed an “overweight” rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial raised their target price on shares of Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Tuesday, December 24th. Finally, Canaccord Genuity Group upped their target price on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $63.14.

Insider Buying and Selling at Vericel

In other Vericel news, insider Jonathan Siegal sold 1,092 shares of Vericel stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total value of $67,693.08. Following the completion of the transaction, the insider now directly owns 1,206 shares of the company’s stock, valued at $74,759.94. This trade represents a 47.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Jonathan Mark Hopper sold 10,000 shares of Vericel stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $58.72, for a total transaction of $587,200.00. Following the completion of the transaction, the insider now directly owns 58,371 shares of the company’s stock, valued at $3,427,545.12. The trade was a 14.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,100 shares of company stock worth $1,206,072. Insiders own 5.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.